eptinezumab
Trade name: Vyepti
mAbapproved
Approved
Feb 21, 2020
Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion. — Wikipedia
Clinical trial activity
27 trials · 9 clinical orgs · 1 marketing orgs
Phase 1
6
Phase 2
17
Phase 3
15
Phase 4
3
Earliest trial started Apr 1, 2012 (NCT01579383)
Timeline
2010s
Indications
Approved for
Mechanism of action
- Calcitonin gene-related peptide 1INHIBITOR
CALCA
- Calcitonin gene-related peptideINHIBITOR
Calcitonin gene-related peptide inhibitor
Inhibits the calcitonin gene-related peptide, or CGRP, a small protein involved in the transmission of, and heightened sensitivity to, pain experienced in migraine.
Kd <20 pM towards CGRP
Approval history
- approvedFeb 21, 2020
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3833320 ↗
- WikipediaEptinezumab ↗
Also known as
- eptinezumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07191145 | Phase 3 | Oct 1, 2025 | University of Toronto |
| NCT06701526 | Phase 4 | Dec 5, 2024 | Lundbeck |
| NCT06428838 | Phase 3 | Sep 30, 2024 | HealthTech Connex Inc., Lundbeck, Royal Columbian Hospital Foundation, University of British Columbia |
| NCT05937152 | Phase 2 | Jan 31, 2024 | Mayo Clinic |
| NCT05897320 | Phase 3 | Jun 8, 2023 | Lundbeck |
| NCT05635604 | N/A | Dec 1, 2022 | University of Copenhagen |
| NCT05452239 | Phase 4 | Jul 1, 2022 | Lundbeck |
| NCT05284019 | Phase 4 | Mar 4, 2022 | Lundbeck |
| NCT05164172 | Phase 3 | Dec 1, 2021 | Lundbeck |
| NCT05074459 | Phase 1 | Sep 27, 2021 | Lundbeck |
| NCT05064371 | Phase 3 | Sep 21, 2021 | Lundbeck |
| NCT05064397 | Phase 3 | Sep 17, 2021 | Lundbeck |
| NCT04965675 | Phase 3 | Jun 30, 2021 | Lundbeck |
| NCT04921384 | Phase 3 | May 29, 2021 | Lundbeck |
| NCT05045781 | Phase 1 | Apr 20, 2021 | Lundbeck |
| NCT04772742 | Phase 3 | Feb 17, 2021 | Lundbeck |
| NCT04688775 | Phase 3 | Dec 23, 2020 | Lundbeck |
| NCT04537429 | Phase 1 | Aug 3, 2020 | Lundbeck |
| NCT04418765 | Phase 3 | Jun 1, 2020 | Lundbeck |
| NCT04336449 | Phase 1 | Apr 1, 2020 | Lundbeck |
Showing 20 of 27 trials
Page 1 / 2
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lundbeck | For profit | 17 | 16 | 3 | 2020 |
| Alder Biopharmaceuticals | For profit | 7 | 7 | 3 | 2012 |
| HealthTech Connex Inc. | For profit | 1 | 1 | 1 | 2024 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2012 |
| Royal Columbian Hospital Foundation | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of British Columbia | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2025 |
9 organizations
Page 1 / 1